The company stated that the authorization allows it to communicate that switching to Zyn reduces the probability of contracting smoking-related illnesses, including mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. Philip Morris contends that this decision will provide American consumers with science-based information regarding the health benefits of transitioning away from combustible tobacco.

Stacey Kennedy, Chief Executive Officer of Philip Morris in the U.S., emphasized that the agency's move ensures adult users have access to verified evidence regarding risk reduction. By securing these orders, the tobacco giant aims to solidify the position of Zyn as a viable alternative for existing smokers looking to mitigate their exposure to the severe health consequences associated with cigarette use.